Pharmaceutical company AstraZeneca said a new drug showed a 72 per cent reduction in the risk of disease progression or death in women with HER2-positive metastatic breast cancer.
Pharmaceutical company AstraZeneca said a new drug showed a 72 per cent reduction in the risk of disease progression or death in women with HER2-positive metastatic breast cancer.